Medicine
Alhemo 60 mg/1.5 mL injection
Alhemo 60 mg/1.5 mL injection is a prescription medicine containing Concizumab for subcutaneous use, marketed by Novo Nordisk, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Store in a refrigerator at 36°F to 46°F (2°C to 8°C) in the original carton to…
Key facts
- Active ingredient (INN)
- Concizumab
- Brand
- Alhemo
- Strength
- 60 mg/1.5 mL
- Dosage form
- Injection
- Route
- Subcutaneous
- Packs
- 1 syringe of 1.5 mL
- Marketing authorisation holder
- Novo Nordisk
- Manufacturer
- Novo Nordisk
- Origin register
- US FDA, United States
- Storage
- Store in a refrigerator at 36°F to 46°F (2°C to 8°C) in the original carton to protect from light. Do not freeze. After first use: Store in a refrigerator at 36℉ to 46˚F (2℃ to 8˚C) or at room temperature below 86˚F (30˚C) for up to 28 days. Do not freeze or store it close to a cooling element in a refrigerator (the part that cools the refrigerator).
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- B02BX10 Concizumab
- HS code (indicative)
- 3002.15Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 19 February 2025
- Identifiers
- RxCUI 2708346, 2708353, 2708356 +3DailyMed set ID 156f6404-1f6f-417f-bcf8-f07a27a82cc1NDC 0169-2084Application BLA761315
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 syringe, plastic in 1 carton / 1.5 mL in 1 syringe, plastic | 0169-2084-15 | Novo Nordisk | 19 February 2025 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Concizumab
Clinical summary
Concizumab is a tissue factor pathway inhibitor antagonist indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult, among other approved uses. It is available as injection for subcutaneous use. MedsAcross supplies Concizumab for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about ConcizumabFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Alhemo prescribing information (Novo Nordisk) · U.S. National Library of Medicine, DailyMed
- Alhemo: European public assessment report (EPAR) · European Medicines Agency
Need Alhemo 60 mg/1.5 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.